Pharmacology and Drug Interactions

Teaches review and management of concomitant medications, restricted therapies, prohibited substances, washout periods, tapering requirements, and abstinence expectations. The competency includes participant counseling, medication reconciliation, sponsor notification, and team coordination when restrictions affect safety or interpretability.

Medication and interaction review

Cluster covering 7 related competencies including: Physiologic safety awareness, Hallucinogen pharmacology and effects, Hallucinogen-assisted therapy knowledge.

Effects and time course

The therapist/facilitator must support structured dose escalation decisions within the individualized dosing regimen. Decisions depend on both patient-reported peak experience and clinical tolerability/safety judgments.

Dose and administration safety

Understand the pharmacology and interaction risks of 5-MeO-DMT/BPL-003, including serotonergic and cardiovascular concerns. This knowledge informs safe preparation, exclusion screening, and monitoring.

Cluster covering 5 related competencies including: Concomitant medication review, Contraindication and interaction awareness, Contraindications, drug effects, and interactions.

Medication and interaction review

Facilitators must understand the expected psychological, physiological, and potential adverse effects of MDMA in order to prepare participants, support the session, and detect complications.

Conduct preparatory sessions that orient the subject, assess readiness, and set expectations for MDMA-assisted psychotherapy. These sessions are used to prepare for safety, adherence, and therapeutic engagement.

The facilitator should know how oral and intravenous dosing relate to onset, duration, and peak effects. This knowledge supports proper session planning, monitoring, and integration timing.

Effects and time course

Teaches monitoring during down-titration or discontinuation of psychiatric medications before dosing. Learners track withdrawal symptoms, symptom worsening, suicidality, and other risks that may emerge during tapering.

Taper and withdrawal coordination

Understand the basic pharmacology and clinical effects of ayahuasca to inform safe facilitation and interpretation of responses. The source identifies dimethyltryptamine as a 5-HT2A agonist and harmine as a monoamine-oxidase A inhibitor.

Competent facilitation requires practical knowledge of dosage ranges, initial dosing, boosters, formulation handling, and administration errors. The handbook stresses both clinical judgment and meticulous procedural care.

Dose and administration safety

Understands the drug’s rapid absorption profile and lack of accumulation with repeated dosing. Uses this knowledge to anticipate timing of effects and safety observations.

Teaches psychoactive substance pharmacology, expected drug effects, contraindications, and relevant drug-interaction risks. The competency supports safer screening, medication review, participant education, and clinical decision-making.

Understand the proposed mechanisms, phases of effect, and common subjective and physical effects of ibogaine relevant to clinical supervision. This knowledge informs safe monitoring and therapeutic pacing.

Facilitators need basic knowledge of ayahuasca composition, dosing, and interaction risks to support safe administration. The protocol emphasizes dose calculation, substance composition, and monitoring for contraindications.

Tracks dose-dependent changes without assuming full psychedelic effects. This includes recognizing that low-dose exposure may modulate brain activity while remaining sub-psychedelic.

Understand the role of serotonergic mechanisms and the implications of receptor antagonism for acute psychedelic effects. Use this knowledge to interpret responses and co-administration effects.

Recognizes medical factors that may increase risk during inhaled 5-MeO-DMT administration. Medical clearance is required before dosing.

Facilitators need knowledge of conditions and medications that may make 5-MeO-DMT unsafe or inappropriate. They should identify possible interactions and discuss them clearly before participation.

Recognize when post-session exhaustion or discomfort may warrant supportive symptom management and understand the limited use of sedatives in the protocol. The facilitator must balance comfort with safety and document any sedating agents used.

Recognize and classify events relevant to abuse liability, intoxication, misuse, dissociation, and overdose. The protocol specifies preferred terms that should be considered as AESIs when appropriate.

Ability to correctly deliver the investigational inhaled drug using standardized vaporization procedures and participant instructions. Safe and accurate administration is central to the dosing protocol.

The therapist/facilitator must understand potential drug-interaction concerns and formulation-related differences that could alter tolerability or safety. The source mentions caution with antiemetics and alternative preparations.

Providers must know that ibogaine does not treat benzodiazepine withdrawal and that sudden cessation can be dangerous. Benzodiazepine-dependent patients should not be told to stop abruptly.

Use supportive anxiolytic or hypnotic medication only when allowed and clinically indicated. This requires careful judgment to balance comfort, safety, and preservation of the session’s integrity.

Use pharmacogenetic information to anticipate altered ibogaine metabolism and exposure. The study identifies CYP2D6 activity as a major determinant of ibogaine clearance.

Knows the purpose and indications of medications maintained for side effect management or emergency use during KAP. Can explain how these medications relate to specific risks.

Understand the common and serious adverse effects, interaction risks, and monitoring needs of escitalopram. This includes cardiac, psychiatric, sexual, and withdrawal-related concerns.

Interprets mescaline responses in light of the study population and design. Understands that findings from healthy subjects may not directly generalize to clinical populations or unsupervised use.

Knows the use of ibogaine as a detoxification agent in medical and nonmedical settings and understands that its mechanism of action is novel and not fully established.

Understand the basic rationale for ibogaine’s proposed effects in substance use disorders. This includes its reported ability to ease withdrawal, reduce craving, and act through multiple neurotransmitter systems.

Facilitators should understand the therapeutic and adverse-effect context of psilocybin and comparator antidepressant treatment, since the trial directly compared psilocybin with escitalopram.

Identify concurrent medications or recent drug exposures that may interact dangerously with ibogaine. The clinician/facilitator must understand that ibogaine can potentiate other drugs and that certain psychiatric medications or toxic agents may contraindicate treatment.

Screen for co-medications that may prolong QTc or affect CYP2D6 metabolism. This is critical to reduce confounding and prevent additive toxicity.

Therapists must understand clinically significant drug interactions with ibogaine, including QT-prolonging, serotonergic, centrally acting, and CYP2D6-related medications. This knowledge informs screening, tapering, and dosing decisions.

Understand the intranasal administration procedure and related local adverse effects. The facilitator must support safe delivery and monitor nasal reactions.

Prepare participants to correctly use nicotine replacement therapy when assigned to the control arm. Facilitators must provide education, dosing instructions, and side-effect guidance.

Understands core pharmacokinetic concepts needed to interpret study findings and guide safety observation. Recognizes dose-linear exposure changes and elimination characteristics relevant to monitoring windows.

Understand ibogaine, noribogaine, and noribogaine glucuronide disposition and how exposure relates to clinical effects. This knowledge supports safe interpretation of observed toxicity and response.

Understands the dose-dependent pharmacokinetics and expected duration of oral mescaline effects. Can anticipate onset, peak, and offset based on the measured human PK/PD profile.

Initiates, uptitrates, and monitors quetiapine XR augmentation in the comparator arm according to age-specific schedules and tolerability. Recognizes the therapeutic minimum and discontinuation triggers.

Use rescue medications only after non-medical interventions have failed, and only by the study site-designated physician. Selection must consider local standard of care, subject history, and QTc risk.

The facilitator should understand the administration context for the intervention. The source highlights inhalation as the studied route and its rapid onset.

Facilitators need working knowledge of administration routes because onset, duration, intensity, and tolerability vary substantially. This informs preparation, monitoring, and participant education.

Administers repeated sublingual microdoses of 5-MeO-DMT in a controlled clinical trial setting. Must follow the assigned dose schedule and maintain blinding across active and placebo conditions.

Know that ayahuasca composition can vary and that chemical characterization matters. Facilitators or clinical teams should understand the potency and stability of the administered brew.

The intervention involved two dosing sessions with either low-dose or high-dose LSD, implying facilitators need knowledge of session-based LSD administration frameworks. This includes understanding that psychotherapy support is paired with specified dosing regimens.

Recognize that current evidence does not establish the lowest effective or safest exposure for ibogaine. Facilitators must understand the uncertainty surrounding efficacy at reduced doses.

Cluster covering 2 related competencies including: Psilocybin prescribing fundamentals, Prescribing fundamentals for psychedelic treatment.

The page explicitly notes medication interactions, contraindications, and risk management for prescribers. This indicates training in identifying unsafe combinations and excluding or delaying treatment when needed.

Learners are taught to design custom protocols for both microdosing and macrodosing based on client goals. The page also references microdosing formulas and practical application of timing and dosage nuances.

Therapists/investigators must understand the medical suitability requirements for LSD-assisted psychotherapy and coordinate medication washout and concomitant medication review. This includes recognizing drug-drug interaction risks and contraindications.

Taper and withdrawal coordination

Monitor and respond to the expected sympathomimetic effects of MDMA. The therapist/facilitator must be alert to transient increases in blood pressure, pulse, and related cardiac symptoms.

Cluster covering 3 related competencies including: Ethical psychedelic facilitation, Safe, legal psychedelic care facilitation, Ethical decision-making in psychedelic facilitation.

Monitors for potential adverse effects associated with ibogaine administration and the detoxification period, even though the abstract primarily reports outcomes rather than specific events.

Understand that ibogaine has a significant toxicity profile, especially cardiotoxicity. Fatalities have been temporally associated with use, often in the setting of medical comorbidity, co-use, or electrolyte imbalance.

Monitors patients closely during treatment because serious adverse outcomes may occur. Safety monitoring is essential given that one participant died during treatment in the study.

Understand the expected acute physiological effects of BPL-003 and monitor for clinically meaningful changes. The facilitator should recognize that transient blood pressure and heart rate increases may occur.

Assess for cerebellar adverse effects such as ataxia during and after ibogaine administration. The source indicates ataxia is likely driven by ibogaine exposure and should be tracked systematically.

Understands and monitors concentration-related cardiac risk, especially QTc prolongation, in participants receiving noribogaine or similar agents. Uses ECG findings to support safe trial conduct and participant protection.

Knows the conditions that may disqualify a person from ketamine treatment and can apply that knowledge during screening. Recognizes medical, psychiatric, pregnancy-related, and substance-related contraindications.

Ability to administer LSD in a psychotherapy setting using the regimen described in the source. The therapist/facilitator must understand session-based dosing and treatment course structure.

Respond promptly to complications arising during ibogaine-supported detoxification. Facilitators need a clear escalation plan for QTc prolongation and intolerable withdrawal.

Support patients through acute opioid withdrawal during ibogaine treatment when withdrawal symptoms are present. The source describes use of oral hydromorphone for symptom relief within the protocol.

The course teaches learners to distinguish between classic psychedelics and emerging therapies within therapeutic applications. This is a foundational comparative literacy competency rather than a protocol-specific skill.